David G. Kalergis

Diffusion Pharmaceuticals LLC develops and manufactures pharmaceutical products. The firm develops trans sodium crocetinate for use in cancers types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. The company was founded by Matthew W. Hantzmon, John L. Gainer, and David G. Kalergis in February 2001 and is headquartered in Charlottesville, VA.

Pharmaceutical Research Associates, Inc. engages in the provision of clinical research services. It focuses on therapeutic, global regulatory affairs, and pharmacovigilance and patient safety. The company was founded in 1982 and is headquartered in Raleigh, NC.

Virginia National Bank provides banking and financial services. The firm operates through two segments: The Commercial Bank and VNB Trust. The Commercial Bank segment involves making loans and generating deposits from individuals and businesses. The VNB Trust segment offers services, which include investment management, trust account administration and estate planning. It offers personal banking, business banking and treasury management services. The company was founded on July 29, 1998 and is headquartered in Charlottesville, VA.

Virginia Biotechnology Association promotes the biotechnology industry. The private company is based in Richmond, VA. The company was founded in 1992 by Terry R. Woodworth. John L. Newby has been the CEO of the company since 2019.

RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL.

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Atelerix Life Sciences, Inc. is a pharmaceutical company that is developing a new drug, ATLX-0199, to address the unmet need of opioid-induced respiratory depression (OIRD) in surgical patients. The company is based in Charlottesville, VA. Atelerix Life Sciences was founded by David G. Kalergis, Benjamin Gaston, James Bates, and Stephen Lewis, with David G. Kalergis serving as the CEO since incorporation. The current drug for OIRD, Naloxone, is problematic and used infrequently because it reverses pain relief. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia.